Novavax (NVAX) shares have soared nearly 300% in the past month to $19.56 per share following a series of positive news.

Novavax shares were up about 17% on Thursday morning after rising to more than $23 per share, though this is still far from the pandemic highs of nearly $300 per share in 2021.

Novavax announced that the FDA has set April 2025 as the deadline to take action to either fully approve or deny the company’s vaccine for commercial use.